Key result
Synthetic neutral endopeptidase 24.11 inhibitors undergo evaluation for hypertension and CHF via prolonged ANP activity.
Neutral endopeptidase inhibitors are being evaluated as potential therapies for hypertension and heart failure by prolonging the activity of atrial natriuretic peptide.
NEP 24.11 inhibitors remain investigational for hypertension and HF; leaves open their clinical role pending randomized evidence.
A limited number of ectoenzymes appear to be involved in the inactivation of circulating-regulatory peptides. Neutral endopeptidase 24.11, a metallopeptidase, is known to inactivate atrial natriuretic peptide (ANP), a substance with diuretic, natriuretic, and vasodilatory effects. Synthetic inhibitors of endopeptidase 24.11, which can prolong the activity of ANP, are currently available. These agents are being evaluated as possible innovative therapies for patients with hypertension and congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Achilihu et al. (1991) conducted a review in Hypertension and congestive heart failure. Neutral endopeptidase inhibitors was evaluated. Synthetic inhibitors of neutral endopeptidase 24.11, which prolong the activity of atrial natriuretic peptide, are being evaluated as therapies for hypertension and congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from The Journal of Clinical Pharmacology